NBL1 Human

The NBL1 gene product is a secreted protein that acts as a bone morphogenetic protein (BMP) antagonist by binding to BMPs and preventing them from interacting with their receptors . This antagonistic action plays a crucial role during growth and development. The protein may also function as a tumor suppressor, particularly in neuroblastoma, by preventing cells from entering the final stage (G1/S) of the transformation process .

Neuroblastoma is the most common extracranial solid tumor in children, typically diagnosed by the age of 5 . It arises from neural crest cells, which are a group of neuronal cells that migrate from the spinal cord to form many structures, including the sympathetic nervous system, during fetal development . The NBL1 gene has been implicated in the suppression of tumorigenicity in neuroblastoma, making it a significant focus of research in understanding and potentially treating this malignancy .

The clinical relevance of NBL1 extends beyond its role in neuroblastoma. It is also associated with other conditions such as granulomatous dermatitis . The protein’s ability to inhibit BMP signaling suggests it could be a target for therapeutic interventions in diseases where BMP signaling is dysregulated.

Research into NBL1 continues to uncover its various roles and mechanisms. The recombinant form of this protein, Neuroblastoma 1 (Human Recombinant), is used in research to study its function and potential therapeutic applications. By understanding how NBL1 interacts with BMPs and other signaling pathways, scientists hope to develop new treatments for neuroblastoma and other related conditions.